Pluristem renamed Pluri Inc., ticker PLUR, pivots to multi-industry cell-based platform

Pluri Inc.

Name change from Pluristem Therapeutics Inc. to Pluri Inc. effective July 26, 2022.
Stock ticker symbol changes to 'PLUR' on Nasdaq Global Market.
CEO Yaky Yanay outlines strategic pivot to cell-based technology for food-tech, agri-tech, and biologics.
Commercialization strategy includes licensing and joint ventures ('Pluri focus units') with separate funding and management.
Continues medical research but expands into non-medical cell-based solutions via partnerships.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.